Statins as anti-cancer therapy; Can we translate preclinical and epidemiologic data into clinical benefit?

Young Kwang Chae*, Muhammad Yousaf, Mary Kate Malecek, Benedito Carneiro, Sunandana Chandra, Jason Kaplan, Aparna Kalyan, Antonella Sassano, Leonidas C. Platanias, Francis Giles

*Corresponding author for this work

Research output: Contribution to journalArticle

21 Scopus citations

Abstract

Statins, the most commonly prescribed class of drug, have demonstrated effects beyond cholesterol reduction including anti-tumor and immunomodulatory properties. Several epidemiological studies have suggested an anti-neoplastic effect of statins evidenced by reductions in cancer incidence and cancer-related mortality. Clinical trials on statins as part of therapy for cancer have generated interest in the oncology community. Statins have been investigated for a variety of cancers, early and late stage, and in combination with chemotherapy and radiation. So far promising results have been reported with statin use in pediatric brainstem tumors, early stage breast cancer, hepatocellular carcinoma (HCC), colorectal cancer (CRC), refractory or relapsed multiple myeloma (MM), and refractory acute myeloid leukemia (AML). There is still much investigation to be completed to determine which subtypes of patients benefit from statin therapy, how statins may potentiate other anticancer approaches, and the appropriate dosing schedule to use.

Original languageEnglish (US)
Pages (from-to)413-427
Number of pages15
JournalDiscovery Medicine
Volume20
Issue number112
StatePublished - Jan 1 2015

    Fingerprint

ASJC Scopus subject areas

  • Medicine(all)

Cite this